HIV

Gut microbiome alterations have been associated with frailty in older individuals with HIV.

"Gut microbiome" is becoming a buzzword in the health care community.

Human genome sequence variations can have a significant impact on the efficacy of HIV antiviral therapy.

HIV-positive children administered antiretroviral therapy have changes in their white matter brain tissue.

Pharmacists can expect to see considerably more information about the implications of pharmacogenetics for drug treatment in every disease state.

Top news of the week from Specialty Pharmacy Times.

Once-daily HIV treatment found to be highly effective and well-tolerated in treating antiretroviral-naïve HIV-1 patients.

How pharmacists can reduce polypharmacy and potentially inappropriate prescribing among the aging HIV population.

With the aging of the HIV-positive population and the necessity of using multiple medications – many of which have significant potential for drug interactions – it's important to look for ways that we can minimize risk for this population.

A derivative of a natural compound could stop HIV replication and prevent a viral rebound.

Developing a vaccine that launches immune attacks against cancer proves to be difficult.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Many children with HIV who are diagnosed with asthma may actually have chronic obstructive lung disease.

Top news of the week from Specialty Pharmacy Times.

Moderately effective vaccine could boost efforts to cure HIV.

Approximately 10% of the HIV population will die from lung cancer.

Individuals with an undetectable HIV viral load are at effectively no risk of transmitting the virus.

Drinking coffee may have more profound survival benefits for patients with HIV and hepatitis C than for the general population.

Researchers evaluate potential reasons why HIV some drug combinations are more effective in certain patients.

Current guidelines for treating children with HIV recommend regular medical visits for the first 2 years after care initiation.

Two-drug combination of injectable, long-acting cabotegravir plus rilpivirine monthly or bi-monthly showed comparable efficacy to a daily 3-drug oral therapy at maintaining HIV-1 viral suppression.

The National HIV Surveillance System tracks retention in care for adults diagnosed with HIV, but does not include children in its assessment.

A synthetic particle awakens dormant HIV cells then knocks them out.

A biochip may be able to detect HIV in a drop of blood and display the results within 10 seconds.

Janssen is seeking FDA approval for its once-daily darunavir-based regimen for HIV.

Pharmacists who are unfamiliar with either the principles of infectious disease or HIV may miss errors.

A fixed-dose combination of bictegravir and emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) was non-inferior to boosted protease inhibitor (bPI)-based regimens in virologically suppressed adults with HIV, according to a recently-published phase 3 study.

Achieving National HIV/AIDs target goal could prevent an estimated 200,000 deaths over 20 years, according to a study recently published in the Journal of Infectious Diseases.